FDA clears QbTest for unbiased evaluation of ADHD treatment

The US Food and Drug Administration (FDA) has cleared the neuropsychological test - QbTest - developed by the Swedish company Qbtech to aid in the evaluation of treatment interventions in patients with ADHD. QbTest is a computer-based test providing clinicians with objective and unbiased decision-making support when diagnosing and treating ADHD in children, adolescents and adults. QbTest is the only test in the world cleared by the FDA for this usage.

Approximately 145 000 patients have undergone a QbTest in Europe and the US. Traditionally, a clinical interview and subjective information from various rating scales, performed by the patient and their immediate family, teachers and others, has been the standard when evaluating treatment effects. This process is complex, involves administrative costs for the clinic and can extend the time to evaluate if the treatment is working. A further limitation is that such evaluations carry significant risk for biased feedback.[1] (http://connect.ne.cision.com#_ftn1) QbTest provides unbiased and objective outcome measurements that can be utilized quickly and easily and is not biased for or against medication or any other treatment.

- QbTest is the first objective test in the world to be cleared by the FDA for treatment evaluation within ADHD. This enables clinicians to better determine effects of treatment and to reduce the risk of over- and undermedication of patients, explains Carl Reuterskiöld, CEO of Qbtech. He goes on to say:

- Each patient responds differently to treatment. QbTest helps to ensure that the right patients get the right treatment faster - an outcome that can increase quality of life for patients.

A Better View of ADHD

QbTest makes it easier for clinicians to identify, rule out and monitor ADHD by providing an unbiased view of the patient's symptoms. By adding QbTest to the clinical pathway, studies show that you can improve diagnostic accuracy, reduce the risk of unidentified ADHD and help to identify patients not responding to treatment.[2] (http://connect.ne.cision.com#_ftn2), [3] (http://connect.ne.cision.com#_ftn3)